Cath Trigwell

588 total citations
9 papers, 365 citations indexed

About

Cath Trigwell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Cath Trigwell has authored 9 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Cath Trigwell's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Cath Trigwell is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Cath Trigwell collaborates with scholars based in United Kingdom, France and United States. Cath Trigwell's co-authors include Urs J. Hancox, Sarat Chandarlapaty, Brett S. Carver, John Wongvipat, Neal Rosen, Howard I. Scher, José Baselga, Charles L. Sawyers, Sarit Schwartz and Elisa de Stanchina and has published in prestigious journals such as Cancer Cell, Cancer Research and Clinical Cancer Research.

In The Last Decade

Cath Trigwell

9 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cath Trigwell United Kingdom	6	220	150	136	53	52	9	365
Donna-Michelle Smith United Kingdom	9	151 0.7×	213 1.4×	100 0.7×	41 0.8×	57 1.1×	12	363
Gianmarco Motta Italy	9	194 0.9×	127 0.8×	85 0.6×	41 0.8×	80 1.5×	18	395
Woody Han United States	6	188 0.9×	141 0.9×	77 0.6×	28 0.5×	52 1.0×	8	345
Neil T. Conlon Ireland	10	146 0.7×	198 1.3×	67 0.5×	34 0.6×	57 1.1×	25	326
Yu Kataoka Japan	6	213 1.0×	176 1.2×	99 0.7×	27 0.5×	50 1.0×	10	378
Kwee Hyun Suh South Korea	9	141 0.6×	150 1.0×	80 0.6×	78 1.5×	30 0.6×	32	341
Emily Wearne United States	6	159 0.7×	164 1.1×	105 0.8×	20 0.4×	53 1.0×	6	335
Nicole Drezner United States	8	160 0.7×	233 1.6×	218 1.6×	50 0.9×	73 1.4×	13	430
Jennifer Kahler United States	6	302 1.4×	300 2.0×	283 2.1×	35 0.7×	79 1.5×	10	561
Deepa Prabhavalkar United States	2	228 1.0×	295 2.0×	183 1.3×	67 1.3×	29 0.6×	2	477

Countries citing papers authored by Cath Trigwell

Since Specialization

Citations

This map shows the geographic impact of Cath Trigwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cath Trigwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cath Trigwell more than expected).

Fields of papers citing papers by Cath Trigwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cath Trigwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cath Trigwell. The network helps show where Cath Trigwell may publish in the future.

Co-authorship network of co-authors of Cath Trigwell

This figure shows the co-authorship network connecting the top 25 collaborators of Cath Trigwell. A scholar is included among the top collaborators of Cath Trigwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cath Trigwell. Cath Trigwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2016). Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers. Molecular Cancer Therapeutics. 15(5). 877–889. 36 indexed citations

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2015). Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers. Cancer Research. 75(15_Supplement). 2665–2665. 1 indexed citations

Schwartz, Sarit, John Wongvipat, Cath Trigwell, et al.. (2014). Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ. Cancer Cell. 27(1). 109–122. 172 indexed citations

Schwartz, Sarit, Brett S. Carver, John Wongvipat, et al.. (2014). Abstract 4774: The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling. Cancer Research. 74(19_Supplement). 4774–4774. 1 indexed citations

Barlaam, Bernard, Judith Anderton, Peter Ballard, et al.. (2013). Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Medicinal Chemistry Letters. 4(8). 742–746. 31 indexed citations

Marshall, Gayle, Susan Ashton, Georgina Speake, et al.. (2013). Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease.. Cancer Research. 73(8_Supplement). 912–912. 1 indexed citations

Hickinson, D. Mark, Teresa Klinowska, Georgina Speake, et al.. (2010). AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer. Clinical Cancer Research. 16(4). 1159–1169. 95 indexed citations

Barlaam, Bernard, David Acton, Peter Ballard, et al.. (2008). Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(6). 1799–1803. 10 indexed citations

Barlaam, Bernard, Peter Ballard, Robert H. Bradbury, et al.. (2007). A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(2). 674–678. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact